References

Risk factors for death from Stenotrophomonas maltophilia bacteremia

10.1016/j.jiac.2018.03.011 · ExternalCitation · doi-reference

Risk factors for mortality in Stenotrophomonas maltophilia bacteremia—A meta-analysis

10.1080/23744235.2024.2324365 · ExternalCitation · doi-reference

Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy

10.1093/cid/ciaa778 · ExternalCitation · doi-reference

10.1093/cid/ciae403

10.1093/cid/ciae403 · ExternalCitation · doi-reference

Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: Implications for susceptibility breakpoints

10.1093/jac/dkac018 · ExternalCitation · doi-reference

Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model

10.1093/jac/dkac304 · ExternalCitation · doi-reference

Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections

10.1093/jac/dkv456 · ExternalCitation · doi-reference

Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia

10.1093/jac/dkz116 · ExternalCitation · doi-reference

Clinical challenges treating Stenotrophomonas maltophilia infections: An update

10.1093/jacamr/dlac040 · ExternalCitation · doi-reference

Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals

10.1093/ofid/ofab644 · ExternalCitation · doi-reference

Management of Stenotrophomonas maltophilia Infections in Critically Ill Children

10.1097/inf.0000000000001959 · ExternalCitation · doi-reference

Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017

10.1097/md.0000000000019250 · ExternalCitation · doi-reference

Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia

10.1128/aac.00559-20 · ExternalCitation · doi-reference

Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits

10.1128/aac.00618-22 · ExternalCitation · doi-reference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

10.1128/aac.01433-20 · ExternalCitation · doi-reference

In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia

10.1128/aac.01436-20 · ExternalCitation · doi-reference

Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

10.1128/aac.01682-13 · ExternalCitation · doi-reference

In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth

10.1128/aac.02167-21 · ExternalCitation · doi-reference

Stenotrophomonas maltophilia: An emerging global opportunistic pathogen

10.1128/cmr.00019-11 · ExternalCitation · doi-reference

Advances in the Microbiology of Stenotrophomonas maltophilia

10.1128/cmr.00030-19 · ExternalCitation · doi-reference

Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia

10.1128/cmr.11.1.57 · ExternalCitation · doi-reference

Evaluating Metabolic Pathways and Biofilm Formation in Stenotrophomonas maltophilia

10.1128/jb.00398-21 · ExternalCitation · doi-reference

Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States

10.1128/mbio.00405-19 · ExternalCitation · doi-reference

Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: Clinical characteristics and risk factors for 28-day mortality

10.1128/spectrum.01011-24 · ExternalCitation · doi-reference

Cefiderocol: Early clinical experience for multi-drug resistant gram-negative infections

10.1128/spectrum.03108-23 · ExternalCitation · doi-reference

Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia Infections in Hospitalized Patients

10.1177/10600280231201850 · ExternalCitation · doi-reference

The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants

10.1186/gb-2008-9-4-r74 · ExternalCitation · doi-reference

10.1186/s12879-024-10293-4

10.1186/s12879-024-10293-4 · ExternalCitation · doi-reference

Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: A nationwide retrospective study

10.1186/s13054-019-2649-5 · ExternalCitation · doi-reference

Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: A multicenter, observational, real-world study

10.1186/s13613-023-01144-7 · ExternalCitation · doi-reference

Stenotrophomonas maltophilia bacteremia in children: Risk factors and mortality rate

10.1186/s13756-021-00888-w · ExternalCitation · doi-reference

10.1371/journal.pone.0037375

10.1371/journal.pone.0037375 · ExternalCitation · doi-reference

10.21203/rs.3.rs-1212986/v1

10.21203/rs.3.rs-1212986/v1 · ExternalCitation · doi-reference

10.3389/fonc.2021.752037

10.3389/fonc.2021.752037 · ExternalCitation · doi-reference

Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults

10.3390/pharmaceutics3010053 · ExternalCitation · doi-reference